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Objectives: To capture changes in the quality of life (QoL) occurring in patients with osteoarthritis (OA)
during treatment with non-specific non-steroidal anti-inflammatory drugs (NSAIDs) and to identify factors
that predict such changes.
Methods: A naturalistic, prospective follow up of 783 patients with OA in whom primary care physicians
decided to start treatment with non-selective NSAIDs. Short Form-36 (SF-36) and the Western Ontario and
McMaster Universities OA index (WOMAC) were assessed at baseline and after 3 months. Baseline
results were compared with QoL values in 4800 subjects randomly selected from the general population.
Multiple regression analysis was performed to identify determinants of QoL at baseline and measures
influencing changes in SF-36 or WOMAC during follow up.
Results: All QoL dimensions were significantly (p,0.01) decreased in patients with OA compared with
controls. Significant improvement (p,0.05) in four dimensions of the SF-36 (vitality, role emotional, role
physical, bodily pain) and in all components of the WOMAC was seen between baseline and month 3.
Older age, female sex, longer duration of OA, and a higher number of comorbidities were the major
determinants of a poor QoL at baseline. Maximal benefit from non-specific NSAIDs was seen in patients
with the most severe impairment in QoL and the shortest duration of OA.
Conclusion: OA negatively impacts all dimensions of the QoL. Non-specific NSAIDs improve the QoL in
patients with OA treated in a ‘‘real life setting’’. The profile of patients receiving maximal benefit from such
treatment may be of interest for health providers, enabling them to decide who should preferentially be
given cytoprotective treatments or coxibs.
O
steoarthritis (OA) is a chronic degenerative joint
disease and a major source of disability in elderly
people.1 Disability may be characterised as the
impaired performance of expected socially defined life tasks,
in a typical sociocultural and physical environment.2 3 Elderly
people with physical and psychosocial disability have been
repeatedly shown to have lower levels of health related
quality of life (QoL) than matched controls,4 5 a condition
also associated with the presence of various degrees of OA.6 7
Health related QoL outcomes provide an effective means for
clinicians to make clinically sensible decisions by providing
further insight into the benefits and drawbacks of treatment
options.7
Although there are few doubts, today, that arthritic
conditions may significantly alter the QoL, particularly in
elderly people,6 7 there is still some debate about the relative
impact of OA on the different dimensions of QoL,8 the
respective usefulness of generic or specific instruments to
measure QoL in OA,6 7 the determinants of disability or QoL
changes over time,2 and the impact of treatments for OA on
QoL.7 9
Symptomatic treatments of OA consist of non-pharmaco-
logical as well as pharmacological interventions, including
the use of non-steroidal anti-inflammatory drugs (NSAIDs).
NSAIDs reduce inflammation, alleviate pain, and maintain
functional activity. However, conventional (non-selective)
NSAIDs may induce upper gastrointestinal (GI) side effects,
which may, in turn, negatively impact the QoL.10
We designed the present naturalistic trial to assess
whether patients starting treatment with a conventional
NSAID for the symptomatic management of OA had an
impaired QoL. We prospectively followed up the cohort to
capture changes in QoL over time and to identify the main
determinants of such changes. We compared the information
obtained from generic and specific health related QoL
instruments.
METHODS
This study is an ancillary protocol to a naturalistic,
prospective survey, designed with the primary objective of
evaluating gastroprotective drug (GPD) co-prescriptions in
patients treated with NSAIDs by general practitioners (GPs).
Fifty primary care physicians—that is, Belgian GPs, were
asked to recruit 50 consecutive patients each, for whom they
felt it was appropriate, based on their normal practice, to start
treatment with non-selective NSAIDs. Data were collected
between August 2001 and December 2002. Cyclo-oxygenase-2
inhibitors (coxibs) were not marketed and reimbursed in
Belgium before September 2002. Men and women aged over
35 years were included. One hundred patients were aged
between 35 and 50 and 683 patients were older than 50.
The only exclusion criteria were previous exposure to
investigational coxibs at any time, exposure to NSAIDs
Abbreviations: coxibs, cyclo-oxygenase-2 inhibitors; GI,
gastrointestinal; GPD, gastroprotective drug; GPs, general practitioners;
NSAIDs, non-steroidal anti-inflammatory drugs; OA, osteoarthritis; QoL,
quality of life; RCTs, randomised controlled trials; SF-36, Short Form-36;
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during the past 3 months, and concomitant use of
corticosteroids, anticoagulants, or low dose aspirin. GPs
were instructed to prescribe NSAIDs (type, dose, and
duration) according to their usual standard of care. To
speed up recruitment, the number of GPs participating in
the survey was increased to 66.
Patients were divided into three diagnostic groups, based
on the underlying disease leading to the NSAID prescription:
OA, chronic back pain without OA, and any other medical
condition. At baseline, we collected information on a previous
history of GI disorders and GPD use during the past
3 months. Patients were also asked to report spontaneously
any chronic and/or severe disorders they had had during the
previous 6 months. A list of chronic conditions was then
presented to the participants in order to exclude any
forgotten disease. Patients were seen by their GPs after
3 months and information was collected on NSAID intake
(persistence), occurrence of GI adverse reactions, and GPD
prescriptions (nature and motivation).
At baseline and after 3 months, patients from the OA
group were asked to complete two health related QoL
instruments: the Medical Outcomes Study Short Form-36
(SF-36) and the Western Ontario and McMaster Universities
OA Index (WOMAC).
The SF-36 is a generic health related QoL instrument
which consists of 36 items that measure eight dimensions of
health status as reported by the patient. Four dimensions
refer to physical health: limitations in physical functioning
due to health, limitations in usual role activities due to
physical health, bodily pain, and perceptions of health in
general. Four dimensions allude to mental health: vitality
(energy and fatigue), limitations in social activities due to
physical or emotional health, limitations in usual role
activities due to personal or emotional problems, and general
mental health (psychological distress and wellbeing).11 12
These dimensions are scored from 0 to 100, with lower
scores indicating lower levels of health related QoL. One of
the strongest attributes of the SF-36 is its consistently high
levels of reliability (test-retest and internal consistency) and
validity (content, concurrent, criterion, construct, and pre-
dictive).12 13 The SF-36 has been broadly applied and
validated for the measurement of health outcomes in diverse
languages (including French14 15) and for various conditions
(including OA).
Besides this generic instrument, we also used the WOMAC,
which is a validated and self reported health status
instrument for measurement of the symptoms of OA of the
hips and knees. The WOMAC separately deals with severity of
joint pain (5 questions), stiffness (2 questions), and
limitation of physical function (17 questions) in the 48 hours
before assessment. The Likert scale version of the WOMAC
index was used, with each question scored on a scale from 0
to 4, with 0 indicating none and 4 indicating extreme; 20, 8,
and 68 points, therefore, are the worst possible severity scores
of pain, stiffness, and limitation of physical function,
respectively.16
Table 1 Type, dose, and duration of the five NSAIDs most used during the study period
NSAIDs n
Mean daily
dose (mg) 95% CI
Less than
1 week 1–4 Weeks 1–3 Months
(n) (n) (n)
Piroxicam 232 20.04 19.69 to 20.39 113 24 81
Nimesulide 117 178.88 170.14 to 187.62 14 58 41
Meloxicam 100 19.32 13.55 to 25.09 8 46 43
Ibuprofen 129 1055.2 975.41 to 1134.99 16 72 36



































Figure 1 Mean values of the various dimensions of the SF-36, by sex, in 783 subjects with OA and in a control cohort obtained from a random
sample of 4800 Belgian citizens.
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Owing to the naturalistic approach of our study, no direct
control, using either a healthy population or an untreated OA
population, was possible. We compared the baseline values of
the SF-36 with those found in a historical control—that is, a
representative random sample of 4800 Belgian subjects, aged
over 45 years, who had taken part in a population health
survey organised by the Belgian National Social Security
Institute (INAMI-RIZIV) and for which SF-36 data were
available. We have exhaustively described the methodology
of recruitment of this population sample in a previous
publication.17 Matched subjects were selected to constitute a
control group. The two matching criteria were age and sex.
The whole database allowed us to recover three matched
subjects for each patient with OA.
Statistics
An unpaired Student’s t test was used for comparison of the
SF-36 values found in the OA group and in the historical
controls. SF-36 or WOMAC values between inclusion and the
month 3 visit were assessed by a paired Student’s t test.
Multiple regression analysis was performed to identify the
determinants of health related QoL at baseline in order to
validate our population in comparison with previous studies
and the measures influencing the changes in the WOMAC
and SF-36 seen during the 3 months of the trial.
RESULTS
Seven hundred and eighty three patients with OA were
included in the present trial. They had a mean (SD) age of
66.5 (12.5) years, and included 533 (68.1%) women. They
reported a mean number of 2.2 comorbidities. At base-
line, the NSAIDs most frequently prescribed by the GPs
were piroxicam (n=205), ibuprofen (n=109), diclofenac
(n=112), nimesulide (n=93), and meloxicam (n=92).
Altogether, these five most commonly prescribed NSAIDs
totalled 611 (78%) of the GPs prescriptions. Table 1 shows the
type, mean daily dose, and duration of the five NSAIDs most
commonly used during the study. Only 18 patients consulted
a physical therapist during the 3 month follow up.
The SF-36 questionnaire was available for all patients at
baseline and after 3 months. Valid data were obtained for all
dimensions of the SF-36 in more than 94% at baseline and in
more than 93% of the subjects after 3 months. At baseline
and after 3 months 593 (75.7%) and 586 (74.8%) subjects
filled the WOMAC questionnaire, respectively. Figure 1
shows the values of the various dimensions of the SF-36,
by sex, at baseline, in our OA population and in the historical
cohort. Values were significantly lower, for all dimensions
and for both sexes in comparison with the historical controls
(age 67.7 (11.0) years, percentage of women 68.4%, number
of comorbidities 1.9) (fig 1). When we adjusted for age and
sex, all dimensions of the SF-36 were also significantly lower
for patients with OA than for the historical controls.
Table 2 reports the baseline and 3 month values of the
WOMAC in the OA population, for both sexes and for the
total population. From baseline to the 3 month evaluation, a
significant improvement (p,0.05) was observed for the
domains of vitality, role physical, role emotional, and bodily
pain (fig 2). The values of the total WOMAC index and each
of the subscales were significantly (p,0.05) improved
between baseline and month 3 (table 2).
For most dimensions of the SF-36 (except social function-
ing and physical role), and for all components of the
WOMAC, the multiple regression analysis identified sex of
Table 2 Mean values of the total WOMAC index and its subscales for the entire OA
group, men, and women, at baseline and after 3 months of follow up
Men Women All
Baseline Month 3 Baseline Month 3 Baseline Month 3
Pain 6.99 6.23 8.72 7.63 8.2 7.19*
Stiffness 3.61 3.33 4.09 3.78 3.95 3.65*
Physical 26.2 24.06 31.92 29.23 30.2 27.62*



































Figure 2 Mean values of the various dimensions of the SF-36 at baseline (.94% of the population) and at 3 months (.93% of the population) in a
sample of 783 patients with OA.
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the patient (men have a better QoL than women) as a
significant and independent predictor of QoL at baseline. An
increased prevalence of comorbidities is linked to a poorer
QoL (SF-36 and WOMAC). For the SF-36 physical function
and mental health dimensions, and for the function and total
scales of the WOMAC, age (QoL decreasing in advanced age)
is also a significant component of the QoL. The duration of
OA is independently related to the QoL in the vitality
dimension of the SF-36 (longer duration of OA decreases
the QoL), but not in the WOMAC.
When assessing, by multiple regression analysis, the
determinants of improvement in the QoL, in patients with
OA treated with conventional NSAIDs, it was found that the
patients with the lowest level of QoL at baseline (SF-36 and
WOMAC) had the greatest improvement in QoL over time. A
low number of comorbidities at baseline was associated with
the greatest improvement in QoL (physical functioning, role
physical, pain, and general health dimensions of the SF-36
and pain subscale of the WOMAC) (table 3 and 4). A shorter
duration of disease (role physical, vitality, and pain in the SF-
36) was also a factor associated with a higher improvement
in QoL after 3 months (table 3).
DISCUSSION
Several studies have previously reported that patients with
OA, with or without comorbidities, are characterised by a
poorer QoL than their peers, particularly in the domains
associated with physical status, but also in those of vitality,
social functioning, and general health.4 6 8 Our results support
these findings, with all dimensions of the SF-36 being altered
in both men and women with OA, compared with a
representative sample of the general population of similar
age and comorbidities.17
We should acknowledge, however, two particular aspects
of our OA cohort. These patients were subjects for whom
primary care physicians identified the need to start treatment
with NSAIDs. This strongly suggests that these patients were
symptomatic at the time of assessment of the QoL. Because
OA may be characterised by phases of flares and respite, the
results we observed, particularly for the pain and the physical
functioning dimensions, may be slightly overestimated
compared with the whole population of patients with OA.
Owing to the naturalistic design of our study, we did not
ask the primary care physicians to perform any additional
investigation to confirm the diagnosis of OA, in addition to
their usual standard of care. We thus cannot exclude the
possibility that some patients were mistakenly included
in this trial and actually had other musculoskeletal
conditions.
The values of the total WOMAC score obtained at baseline
in our OA population reflect a slightly poorer condition than
the one reported following a similar methodology, in a cohort
of similar age (62.4 years) and percentage of women (77.7 %)
in a trial designed to assess the efficacy of a potential
structure modifying agent in knee OA.18 In that particular
study, x ray examinations were performed at the time of the
QoL assessment and showed a population equally distributed
between Kellgren-Lawrence grades 2 and 3. This suggests
that the severity of OA in our cohort could be considered as
moderate to severe. Furthermore, the WOMAC has been
designed to capture the essential elements of pain, stiffness,
and physical functioning in patients with OA of the knee and/
or hip joints and because no skeletal radiography was
systematically performed, we cannot rule out the possibility
that our population included patients with OA at other
locations than the lower limbs. Moreover, subjects presenting
OA in the upper limbs did not answer this questionnaire,
which explains the weaker effective size for the WOMAC
compared with the SF-36.
The five most commonly prescribed NSAIDs represented
78% of the total number of prescriptions, in accordance with
the national prescribing pattern of NSAIDs for GPs and also
in agreement with previous publications performed in similar
settings.19 In this naturalistic study, we did not ask the
patient to complete diaries to record accurately the compli-
ance rates for the NSAIDs. As previously published, such
measures may have a significant impact on the degree of
adherence and persistence of the patient to a drug and this
would have jeopardised the naturalistic character of our
study.
In absence of a control group, reflecting the natural history
of the disease, our observation of a statistically significant
improvement, over 3 months of treatment with conventional
NSAIDs, in the domains of vitality, role physical, role
emotional, and bodily pain evaluated by the SF-36 and in
all dimensions of the WOMAC, remains of limited value.
However, the magnitude of the improvement seen in our
study after 3 months for the dimensions linked to pain (15–
25%) is within the same range as that reported in randomised
clinical trials assessing, in OA of the lower limbs, the
symptomatic efficacy of diclofenac, or meloxicam, two of
the most commonly prescribed NSAIDs in our sample.20 21
Table 3 Multiple regression summary. Determinants of change in the dimensions of the









General health 13.06* 0.007 0.74 20.25* 20.08 21.07*
Physical functioning 20.46* 20.09 2.05 20.21* 20.14 21.45*
Mental health 13.56* 0.05 20.78 20.24* 20.09 20.49
Pain 29.89* 20.06 2.09 20.37* 20.23* 21.6*
Role emotional 25.91* 0.005 1.95 20.4* 20.02 21.57
Role physical 34.59* 20.05 3.26 20.44* 20.41* 22.56*
Social functioning 26.32* 20.08 0.36 20.31* 20.01 20.41
Vitality 28.47* 0.008 20.31 0.76* 20.17* 20.35
*p,0.05.
Table 4 Multiple regression summary. Determinants of
change in the dimensions of the WOMAC between









Pain 0.06 0.007 20.11 20.26* 0.03 0.23*
Stiffness 0.27 0.01 20.09 20.34* 0.01 0.05
Physical 0.63 0.03 20.59 20.2* 0.04 0.44
Total 20.83 0.04 20.4 20.17* 0.07 0.59
*p,0.05.
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In this randomised controlled trial, however, the placebo
effect in the OA population is reckoned to be also about 20%.
There are many explanations of this apparently contradictory
result. Firstly, the ‘‘real life’’ design of our study did not allow
for the inclusion of an untreated control population. Thus we
cannot exclude the possibility that patients had a placebo
effect and that the improvement observed for most of the
dimensions of the SF-36 and for all dimensions of the
WOMAC can be explained by a ‘‘doctor effect’’ rather than by
the NSAID itself. Furthermore, outcomes in randomised
controlled trials (RCTs) have been repeatedly shown to be
influenced by the design of the study and to be rather
different from those seen in daily practice.6 8 22 The popula-
tions being treated in RCTs are usually highly selected groups
and therefore are not always fully representative of the
patients seen in clinical practice. In RCTs, the study group is
as homogeneous as possible because patients with other
possible rheumatic disorders are excluded. Moreover,
patients who are included in RCTs are usually recruited on
the basis of a minimal level of pain above average. The
patterns of prescription, follow up, and data collection are far
from the standards usually achieved in RCTs. For all these
reasons, the results obtained in RCTs are usually greater than
those obtained in ‘‘real life’’ settings.
Another question that could be asked about our results is
whether the WOMAC is the appropriate tool for investigating
pain in patients living in the ‘‘real life’’ setting. From our data
and the observation that a certain proportion of patients
(20%) were not able to complete the WOMAC, we might
reach the conclusion that the WOMAC is more appropriate
for clinical trials than for naturalistic studies. As previously
mentioned, we should, however, keep in mind that the
WOMAC has been specifically designed for the assessment of
pain in patients with OA of the lower limbs and is not fully
validated for OA in other skeletal locations. In our study, the
exact location of OA was not provided by the investigators
(GPs), which may also explain the discrepancy between our
results and those of previous clinical studies performed in OA
of the lower limbs.
NSAID treatment has a marked impact on health related
QoL. Not only pain and stiffness decreased but also the ability
to perform routine tasks improved. Furthermore, in these
patients the vitality and role emotional domains also seemed
to improve, which might be because of their increased ability
to perform and enjoy routine tasks and leisure activities while
experiencing relief from the signs and symptoms of OA.
However, the data concerning the improvement in pain
confirm that the patients did not return to integrity. Figures 1
and 2 show that the differences for SF-36 in the pain domain
ranged from around 42 in the OA group at baseline to 49 after
3 months of treatment, whereas the control group scored
about 67. Nevertheless, it is necessary to remain cautious in
analysis of the results because we do not have a direct
comparison with a control group. Furthermore, most of the
RCTs which tested NSAIDs for the improvement in pain did
not show full pain relief but only a statistically significant
improvement. Bradley et al showed that a low dose of
ibuprofen produces a 30% reduction in the pain caused by
OA.23 Three months is not always sufficient time to allow the
maximal reduction of pain to be reached.
Lin et al report a further meta-analysis exploring the use of
topical NSAIDs in the treatment of OA. This well conducted
study found that topical NSAIDs were better than placebo in
reducing pain and improving function over 2 weeks, but that
these effects were lost 4 weeks later.24 LaMontagna et al
found that improvement in pain and functional capacity with
two different NSAIDs was limited to the first few weeks of
treatment; these measures then returned to baseline levels.
These authors suggested that the treatment period in future
trials with NSAIDs should not exceed 3 months because
there seemed to be little clinical improvement in pain and
function after this period.25 In our study, the OA localisation
was not assessed, and QoL levels are known to be related to
the site of the OA. This lack of information may explain the
weak pain decrease after 3 months of follow up.
We previously reported a statistically significant improve-
ment in four dimensions of the SF-36, but of relatively
marginal magnitude (fig 2). It is generally believed that small
differences in health related QoL may be statistically
significant yet clinically irrelevant. The concept of the
minimal clinically important difference (MCID) has been
proposed to refer to the smallest difference in a score that is
considered to be meaningful or clinically important. It can be
defined generally as the smallest difference in score that the
patients perceive as beneficial and which would then
mandate a change in the patient’s management. Reports of
the SF-36 Health Survey shows that very small differences in
the SF-36 could be interpreted as clinically important.26
Samsa et al concluded that the MCID for the Medical
Outcomes Study Short Form-36 (SF-36) Health Survey is
typically in the range of 3–5 points. This statement implies
that differences in SF-36 scores of 1–2 points are deemed
irrelevant.
Our observation that QoL in OA is negatively impacted by
being a woman, being older, having a great number of
comorbidities, or a longer duration of the disease, is in
accordance with previous cross sectional6 or prospective2
studies searching for factors that predict a severe impact of
OA on physical functioning or QoL. More novative, however,
in our report is that the best potential responders to
conventional NSAIDs, with the greatest effect on QoL, are
patients with a recent onset of OA and with symptoms
severely affecting their QoL at baseline. This finding may be
due to regression to the mean. Patients with lower baseline
scores, reflecting worsening of their health status, have a
higher probability of increasing the score at the follow up
than patients with higher baseline scores, and vice versa. In
the extreme case, at the end of the scale, only one direction of
an effect ?0 is possible: for the SF-36, improvement when
the baseline score is 0 (ceiling effect) and worsening when
the baseline score is 100 (floor effect).27 28
Although conflicting results have been obtained about the
overall benefit of non-specific NSAIDs on the QoL in arthritic
patients, mainly owing to the negative impact generated by
their GI toxicity,7 10 a few studies have aimed at defining the
profile of patients who might expect the greatest benefit from
such treatment in OA. To the best of our knowledge, this
study is the first examining this question in a naturalistic
design. From the perspective of a rational use of health
resources, however, it is critically important to target patients
with the highest expected benefit/risk ratio. A high number
of comorbidities at baseline is detrimental to improvement in
the QoL seen during the treatment of OA with NSAIDs. This
is particularly true when assessing QoL with the SF-36,
known to lack specificity for OA. Treatment with NSAIDs
targets pain and function, the major symptoms of OA, but
probably does not have a positive effect on the clinical
expression and the impact on QoL of most comorbidities. This
is in accordance with our observation that the best
responders to NSAIDs, are those patients with OA with the
highest impact of OA on the QoL at baseline. NSAIDs
improve OA symptoms (pain, function) and subsequently
alleviate the impact of OA on the QoL. Recent onset of OA is
also a positive factor for response to NSAIDs.
There is no contradiction between these two findings—
namely, that patients whose QoL is severely affected and
those who have a recent onset of OA have a better response to
NSAIDs. A poor relationship has been shown between the
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radiological severity of OA—that is, an indirect expression of
the duration of the disease and the magnitude of OA
symptoms, measured by the WOMAC.29 We previously
reported, from the primary analysis of this study30 that GI
side effects requiring a GPD co-prescription, were signifi-
cantly more common in patients aged 55 and older. The
observation that patients with a recent onset of OA but severe
impact on their QoL are the best responders to non-specific
NSAIDs, whereas elderly patients have a higher risk of
adverse reactions, may be of interest when discussing with
health providers which patients will benefit from cytopro-
tective drugs or coxibs.
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